性结肠炎中的天然多:临床前作用机制和治疗潜力
Chengu Niu1, Jing Zhang2, Patrick I Okolo3
1Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, USA.
International journal of food sciences and nutrition
|November 17, 2025
概括
天然多可以通过减少炎症和调节肠道细菌来治疗性结肠炎 (UC). 进一步的研究支持它们作为UC管理的新型治疗剂的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,治疗选择有限.
- 目前的治疗方法具有中等的疗效,需要新的治疗策略.
- 自然多在UC的临床前和一些临床研究中显示出潜力.
研究的目的:
- 审查支持天然多在性结肠炎治疗潜力的证据.
- 讨论自然多在UC中的作用机制.
- 突出肠道微生物群作为聚醇治疗的目标的作用.
主要方法:
- 在体内研究的审查.
- 对有限的临床试验数据的分析.
- 审查拟议的行动机制.
主要成果:
- 天然多在UC的临床前和临床环境中显示出治疗潜力.
- 关键的机制包括抗炎和抗氧化作用.
- 调节肠道微生物群是一个重要的治疗点.
结论:
- 天然多是性结肠炎治疗的有希望的候选者.
- 多种机制有助于它们的有效性,包括免疫调节和屏障增强.
- 针对肠道微生物群是基于多的UC治疗的一个关键方面.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459
Inflammatory Bowel Disease I: Ulcerative Colitis
880
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
622
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622


